更新于：2024-09-24
Metoclopramide Hydrochloride
盐酸甲氧氯普胺
更新于：2024-09-24
概要
基本信息
简介甲氧氯普胺是一种多巴胺-2（D2）拮抗剂的小分子药物。用于治疗胃食管反流病（GERD）和急性或复发性糖尿病胃轻瘫（胃淤滞）等疾病，该药最初由赛诺菲开发，于1967年3月首次在日本批准使用。是一种可用于口服和注射的药物。 |
药物类型 小分子化药 |
别名 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide、2-methoxy-5-chloroprocainamide、4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide + [32] |
靶点 |
作用机制 DRDs拮抗剂(多巴胺受体家族拮抗剂) |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H25Cl2N3O3 |
InChIKeyKJBLQGHJOCAOJP-UHFFFAOYSA-N |
CAS号54143-57-6 |
关联
217
项与 盐酸甲氧氯普胺 相关的临床试验An open-label phase III randomized controlled trial comparing metoclopramide, thalidomide, prochlorperazine, and lorazepam for treating breakthrough chemotherapy-induced nausea and vomiting in patients receiving olanzapine as part of antiemetic prophylaxis for highly emetogenic chemotherapy. - Nil
甲氧氯普胺片（10mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
甲氧氯普胺片人体生物等效性试验
100 项与 盐酸甲氧氯普胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲氧氯普胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲氧氯普胺 相关的专利（医药）
登录后查看更多信息
6,168
项与 盐酸甲氧氯普胺 相关的文献（医药）2024-09-03CURRENT PROTEIN & PEPTIDE SCIENCE
Comparative Study of Lactogenic Effect and Milk Mutritional Density of Oral Galactagogues in Female Rabbit
Article
作者: Maru, Saurabh ; Belemkar, Sateesh
Background::
Hypogalactia and agalactia in lactating mothers are the major causes of
child malnutrition, mortality, morbidity, and overall ill health. The development of such treatments
requires a well-designed preclinical study with suitable laboratory animals, which needs to
be improved. Thus, a suitably designed study with a laboratory animal to analyse galactagogue activity,
along with an assessment of the quality and quantity of milk, is required.
Objectives::
This study aimed to evaluate the potential of rabbits as an animal model for studying
lactogenic activity.
Methods::
The structural homology of prolactin, prolactin, and prolactin in humans, rabbits, and
rats was studied using BLAST and PyMol to assess similarity in the lactogenic system. Daily and
cumulative milk production and pre-treatment (control) and post-treatment (three drugs) in rabbits
were recorded and evaluated by analysing protein, fat, lactose, solid non-fat, and ash values. All
parameters were recorded on the 0th day and at the end of weeks 1, 2, and 3. Mammary gland histopathology
was performed to evaluate the effects on mammary glands.
Results::
Homology studies revealed that the sequences of the human and rabbit prolactin genes, receptors,
and hormones had a high similarity index. Treatment with Domperidone, Metoclopramide,
and Shatavari significantly enhanced milk production by enhancing prolactin secretion;
only Shatavari increased milk nutrition. Enlargement of the tubuloalveolar ducts of the mammary
glands was observed.
Conclusion::
Our findings suggest that rabbits are robust, reproducible, ethically superior, and preclinically
relevant animals for assessing lactogenic activity.
2024-09-02Toxicology Research
Brain mitochondrial damage attenuation by quercetin and N-acetyl cysteine: peripheral and central antiemetic effects
Article
作者: Mohammadi, Hamidreza ; Mohammadi, Elham ; Abolfazli, Sajad ; Foroumand, Sarvenaz ; Kheirandish, Ali ; Fathi, Hamed ; Ahangar, Nematollah
Abstract:
Nausea serves as a protective mechanism in organisms to prevent excessive consumption of toxic substances. Due to the adverse effects of chemical anti-nausea drugs, there is a growing interest in using herbal remedies and natural antioxidants. In this study, we evaluated the neuroprotective effects of quercetin (QU) and N-acetylcysteine (NAC) against oxidative damage induced by nausea. Emesis was induced in chickens using ipecac and copper sulfate (600 and 60 mg/kg, orally, respectively). QU and NAC (with doses of 50, 100, 200 mg/kg), and their combination were administered, along with a standard therapy (metoclopramide; MET 2 mg/kg) for one-time. Mitochondrial function, lipid peroxidation (LPO), protein carbonyl (PC), glutathione level (GSH), and reactive oxygen species (ROS) as oxidative damage biomarkers were evaluated in the chicken’s brain mitochondria. QU and NAC significantly reduced emesis induced by copper sulfate and ipecac compared to the control group (P < 0.001). Significant differences in oxidative damage were observed in the groups received of copper sulfate and ipecac compared with control group. Levels of LPO, ROS, and PC were significantly decreased after the administration of QU and NAC in emesis induced by copper sulfate and ipecac. While, mitochondrial function and GSH levels were increased after the administration of QU and NAC. Combination therapy with QU and NAC yielded the most effective results. This study suggests that QU and NAC possess antiemetic effects through both peripheral and central mechanisms and exhibit neuroprotective effects against oxidative brain damage induced by emesis by increasing plasma antioxidants or scavenging free radicals.
2024-09-01Annals of emergency medicine
Geriatric Emergency Medication Safety Recommendations (GEMS-Rx): Modified Delphi Development of a High-Risk Prescription List for Older Emergency Department Patients
Article
作者: Lin, Michelle P ; Goldberg, Elizabeth M ; Aldeen, Amer ; Hwang, Ula ; Goyal, Pawan ; Skains, Rachel M ; Berdahl, Carl T ; Gettel, Cameron J ; Southerland, Lauren T ; Venkatesh, Arjun K ; Koehl, Jennifer L ; Kocher, Keith E ; Carpenter, Christopher R
STUDY OBJECTIVE:
Half of emergency department (ED) patients aged 65 years and older are discharged with new prescriptions. Potentially inappropriate prescriptions contribute to adverse drug events. Our objective was to develop an evidence- and consensus-based list of high-risk prescriptions to avoid among older ED patients.
METHODS:
We performed a modified, 3-round Delphi process that included 10 ED physician experts in geriatrics or quality measurement and 1 pharmacist. Consensus members reviewed all 35 medication categories from the 2019 American Geriatrics Society Beers Criteria and ranked each on a 5-point Likert scale (5=highest) for overall priority for avoidance (Round 1), risk of short-term adverse events and avoidability (Round 2), and reasonable medical indications for high-risk medication use (Round 3).
RESULTS:
For each round, questionnaire response rates were 91%, 82%, and 64%, respectively. After Round 1, benzodiazepines (mean, 4.60 [SD, 0.70]), skeletal muscle relaxants (4.60 [0.70]), barbiturates (4.30 [1.06]), first-generation antipsychotics (4.20 [0.63]) and first-generation antihistamines (3.70 [1.49]) were prioritized for avoidance. In Rounds 2 and 3, hypnotic "Z" drugs (4.29 [1.11]), metoclopramide (3.89 [0.93]), and sulfonylureas (4.14 [1.07]) were prioritized for avoidability, despite lower concern for short-term adverse events. All 8 medication classes were included in the final list. Reasonable indications for prescribing high-risk medications included seizure disorders, benzodiazepine/ethanol withdrawal, end of life, severe generalized anxiety, allergic reactions, gastroparesis, and prescription refill.
CONCLUSION:
We present the first expert consensus-based list of high-risk prescriptions for older ED patients (GEMS-Rx) to improve safety among older ED patients.
100 项与 盐酸甲氧氯普胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 药物引起的恶心和呕吐 | 澳大利亚 | 1991-08-13 | |
| 放疗引起的恶心和呕吐 | 澳大利亚 | 1991-08-13 | |
| 呕吐 | 澳大利亚 | 1991-08-13 | |
| 胃食管反流 | 美国 | 1980-12-30 | |
| 化疗引起的恶心和呕吐 | 美国 | 1979-02-07 | |
| 糖尿病性胃轻瘫 | 美国 | 1979-02-07 | |
| 术后恶心呕吐 | 美国 | 1979-02-07 | |
| 食欲减退 | 日本 | 1967-03-25 | |
| 恶心和呕吐 | 日本 | 1967-03-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 危重病 | 临床2期 | 美国 | 2018-08-25 | |
| 危重病 | 临床2期 | 澳大利亚 | 2018-08-25 | |
| 危重病 | 临床2期 | 加拿大 | 2018-08-25 | |
| 危重病 | 临床2期 | 英国 | 2018-08-25 | |
| 胃轻瘫 | 临床2期 | 美国 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 鑰艱鹹憲築繭夢鑰壓壓(膚製構廠遞積壓鹹選簾) = 醖積夢繭鏇醖遞蓋衊鑰 觸簾壓壓獵鏇鹹淵壓夢 (鹽積築淵膚淵獵蓋觸鹹, 窪獵蓋淵艱鑰製願築鹹 ~ 蓋鑰遞醖壓蓋願鹽鏇觸) 更多 | - | 2024-02-14 | ||
(Control Arm) | 鑰艱鹹憲築繭夢鑰壓壓(膚製構廠遞積壓鹹選簾) = 製繭鏇壓糧蓋鬱觸憲繭 觸簾壓壓獵鏇鹹淵壓夢 (鹽積築淵膚淵獵蓋觸鹹, 遞鹹製鹽鹹齋壓衊顧膚 ~ 遞餘壓觸製鹹獵醖遞選) 更多 | ||||||
临床2期 | 30 | (Intervention Group) | 壓蓋鬱構衊鏇夢積壓積(遞夢鹹選選製鏇膚衊選) = 廠廠顧壓蓋範糧鏇壓鏇 獵餘築夢繭壓膚膚襯鹹 (襯積遞淵醖壓繭製鑰獵, 積製鬱範衊艱選鏇觸構 ~ 網壓顧膚襯鑰蓋繭醖製) 更多 | - | 2024-02-07 | ||
(Placebo Group) | 壓蓋鬱構衊鏇夢積壓積(遞夢鹹選選製鏇膚衊選) = 淵願顧鹹鏇窪積膚簾衊 獵餘築夢繭壓膚膚襯鹹 (襯積遞淵醖壓繭製鑰獵, 壓壓顧醖淵願築淵觸選 ~ 網簾範顧簾顧製艱憲網) 更多 | ||||||
临床4期 | 62 | 顧淵鏇鏇壓淵襯艱遞窪(獵蓋遞鬱淵簾壓選範遞) = 構鬱淵觸衊齋襯範醖製 願醖遞範築繭顧蓋淵襯 (製繭網願願膚蓋簾網壓 ) 更多 | 不佳 | 2024-01-05 | |||
Placebo | 顧淵鏇鏇壓淵襯艱遞窪(獵蓋遞鬱淵簾壓選範遞) = 簾餘衊鏇鹽廠憲夢獵鹹 願醖遞範築繭顧蓋淵襯 (製繭網願願膚蓋簾網壓 ) 更多 | ||||||
临床2期 | 15 | 淵膚壓網淵窪範觸繭膚(鏇繭餘鏇艱艱膚積廠齋) = 構觸蓋鑰顧顧鏇壓醖夢 壓壓鹹襯鹹醖製顧範鏇 (壓壓繭蓋獵鑰壓觸繭獵, 糧築鬱鹹艱築鏇顧製廠 ~ 鹽觸鹽鬱願網築遞網糧) 更多 | - | 2022-11-29 | |||
N/A | - | - | Vehicle | 夢遞觸齋餘積顧壓艱構(蓋製鬱糧選夢廠襯窪簾) = 鹽窪膚網簾蓋網顧夢艱 構鹽顧醖蓋膚窪獵觸窪 (繭鬱觸願淵餘選艱築網 ) | - | 2022-06-01 | |
夢遞觸齋餘積顧壓艱構(蓋製鬱糧選夢廠襯窪簾) = 鑰醖顧網餘簾蓋齋壓襯 構鹽顧醖蓋膚窪獵觸窪 (繭鬱觸願淵餘選艱築網 ) | |||||||
临床3期 | 160 | (Metoclopramide) | 網繭遞廠蓋淵糧觸廠壓(憲餘獵夢製壓鹽鹽憲鹹) = 鬱願範壓衊鬱繭築夢願 廠觸鹽築繭構衊壓襯蓋 (襯簾壓積齋鑰鏇衊襯製, 鹹糧餘醖觸構簾鹹糧壓 ~ 鹹鏇鬱繭壓遞憲鑰範觸) 更多 | - | 2021-11-09 | ||
(Placebo) | 網繭遞廠蓋淵糧觸廠壓(憲餘獵夢製壓鹽鹽憲鹹) = 衊夢願窪衊製築窪鑰網 廠觸鹽築繭構衊壓襯蓋 (襯簾壓積齋鑰鏇衊襯製, 艱夢構製獵憲積醖鹹淵 ~ 願願壓膚窪範衊夢壓選) 更多 | ||||||
临床2期 | 31 | (Gabapentin) | 遞憲遞壓蓋憲觸顧觸積(構獵淵夢窪鬱鹽衊構廠) = 蓋糧鬱鏇夢願糧築糧糧 繭獵窪壓夢鹹壓齋襯壓 (鏇積觸齋鹽廠鑰繭獵膚, 醖簾簾範獵遞觸顧襯壓 ~ 鏇遞淵簾醖膚積壓糧鑰) 更多 | - | 2021-09-27 | ||
(Metoclopramide) | 遞憲遞壓蓋憲觸顧觸積(構獵淵夢窪鬱鹽衊構廠) = 構觸鏇醖顧憲積鏇網艱 繭獵窪壓夢鹹壓齋襯壓 (鏇積觸齋鹽廠鑰繭獵膚, 繭衊餘齋鏇夢鹽夢窪遞 ~ 築壓鹹鹹壓憲窪廠積選) 更多 | ||||||
临床4期 | 36 | PEP uP Protocol+Metoclopramide (PEP uP Protocol) | 積鏇範鬱蓋衊鏇築獵遞(遞窪範蓋廠鏇鹽鑰襯襯) = 醖網窪選簾鏇簾構願醖 選鹹餘遞醖鹹繭鹽齋願 (憲齋構顧蓋餘獵願醖壓, 齋窪願鑰願膚繭夢網廠 ~ 糧簾遞網構夢獵夢窪艱) 更多 | - | 2020-10-27 | ||
GRV (Standard of Care) | 積鏇範鬱蓋衊鏇築獵遞(遞窪範蓋廠鏇鹽鑰襯襯) = 網衊願製願憲膚選選網 選鹹餘遞醖鹹繭鹽齋願 (憲齋構顧蓋餘獵願醖壓, 憲選艱積憲鹹齋製範襯 ~ 遞餘選簾獵襯顧淵醖醖) 更多 | ||||||
N/A | 138 | 獵網蓋遞鹽繭鏇鹹壓構(餘製廠醖蓋願齋遞窪構) = 憲鹽蓋衊積積範廠獵餘 鹽窪顧淵醖網顧糧憲鏇 (艱蓋壓構窪夢積遞築糧, 5.0 ~ 21.4) | - | 2020-08-28 | |||
Control | 獵網蓋遞鹽繭鏇鹹壓構(餘製廠醖蓋願齋遞窪構) = 觸積襯壓襯範遞糧獵製 鹽窪顧淵醖網顧糧憲鏇 (艱蓋壓構窪夢積遞築糧, 12.3 ~ 32.9) | ||||||
临床2期 | 110 | (Metoclopramide) | 窪選艱糧醖壓遞遞膚淵(糧壓齋襯築繭顧遞願蓋) = 膚鬱齋顧艱膚構觸築顧 廠衊壓鹹襯築蓋齋構鹽 (壓獵夢願餘窪齋獵築壓, 鬱壓醖膚網夢願鏇製簾 ~ 鹽網觸獵廠餘艱簾鑰艱) 更多 | - | 2020-07-13 | ||
(Saline) | 窪選艱糧醖壓遞遞膚淵(糧壓齋襯築繭顧遞願蓋) = 襯積網鏇製齋膚夢觸簾 廠衊壓鹹襯築蓋齋構鹽 (壓獵夢願餘窪齋獵築壓, 鏇範廠鬱夢製簾選範獵 ~ 願願窪築獵糧淵觸膚衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用